Maintenance treatment for advanced gastric cancer

doi:10.3760/cma.j.issn.1673-422X.2019.07.011

Abstract

Abstract: S-1 and capecitabine are relatively ideal agents for maintenance treatment of advanced gastric cancer. In clinical trials of using immune and targeted drugs for maintenance treatment of advanced gastric cancer, ipilimumab fails to obtain positive results, ramucirumab has not obtained research data, and trial regimens of maintenance treatment with trastuzumab, bevacizumab and avelumab have all shown initial efficacy. Traditional Chinese medicine therapy has shown some effectiveness in maintenance treatment, which still needs further researches.

Key words: Stomach neoplasms, Drug therapy, Maintenance treatment

Yao Yang, Jia Yingjie, Deng Renfen, Li Xiaojiang, Kong Fanming. Maintenance treatment for advanced gastric cancer[J]. Journal of International Oncology, 2019, 46(7): 439-442.

References

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394424. DOI: 10.3322/caac.21492. ［2］ Li W, Zhao X, Wang H, et al. Maintenance treatment of Uracil and Tegafur (UFT) in responders following firstline fluorouracilbased chemotherapy in metastatic gastric cancer: a randomized phase Ⅱ study［J］. Oncotarget, 2017, 8(23): 3782637834. DOI: 10.18632/oncotarget.13922. ［3］中华人民共和国国家卫生健康委员会. 胃癌诊疗规范(2018年版)［J］. 肿瘤综合治疗电子杂志, 2019, 5(1): 5582. DOI: 10.12151/JMCM.2019.0108. ［4］ Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives［J］. World J Gastroenterol, 2016, 22(8): 24032414. DOI: 10.3748/wjg.v22.i8.2403. ［5］刘捷, 林榕波, 范南峰. 老年晚期胃癌替吉奥维持治疗疗效及预后分析［J］. 中华肿瘤防治杂志, 2018, 25(1): 4550. ［6］ He MM, Wang F, Jin Y, et al. Phase Ⅱ clinical trial of S1 plus nanoparticle albuminbound paclitaxel in untreated patients with metastatic gastric cancer［J］. Cancer Sci, 2018, 109(11): 35753582. DOI: 10.1111/cas.13813. ［7］ Pfeiffer P, Qvortrup C, Krogh M, et al. S1 in combination with docetaxel and oxaliplatin in patients with advanced gastroesophageal adenocarcinoma: two parallel phase 1/2a studies［J］. Acta Oncol, 2017, 56(1): 4651. DOI: 10.1080/0284186X.2016.1257865. ［8］ Haag GM, Stocker G, Quidde J, et al. Randomized controlled trial of S1 maintenance therapy in metastatic esophagogastric cancer—the multinational MATEO study［J］. BMC Cancer, 2017, 17(1): 509516. DOI: 10.1186/s1288501734979. ［9］ Moriya K, Shimizu H, Handa S, et al. Incidence of ophthalmic disorders in patients treated with the antineoplastic agent S1［J］. Gan To Kagaku Ryoho, 2017, 44(6): 501506. ［10］ Qiu MZ, Wei XL, Zhang DS, et al. Efficacy and safety of capecitabine as maintenance treatment after firstline chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation［J］. Tumor Biol, 2014, 35(5): 43694375. DOI: 10.1007/s1327701315745. ［11］ Eren OO, Ozturk MA, Sonmez OU, et al. Safety, feasibility, and efficacy of capecitabine maintenance in patients with advanced gastric cancer: a retrospective study［J］. Am J Ther, 2016, 23(6): e1493e1497. DOI: 10.1097/MJT.0000000000000156. ［12］ Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial［J］. Lancet, 2010, 376(9742): 687697. DOI: 10.1016/S01406736(10)61121X. ［13］ AbdelRahman O, Helbling D, Schmidt J, et al. Treatmentrelated death in cancer patients treated with immune checkpoint inhibitors: a systematic review and metaanalysis［J］. Clin Oncol (R Coll Radiol), 2017, 29(4): 218230. DOI: 10.1016/j.clon.2016.11.007. ［14］ IlhanMutlu A, Taghizadeh H, Beer A, et al. Correlation of trastuzumabbased treatment with clinical characteristics and prognosis in HER2positive gastric and gastroesophageal junction cancer: a retrospective single center analysis［J］. Cancer Biol Ther, 2018, 19(3): 169174. DOI: 10.1080/15384047.2017.1414759. ［15］ Palacio S, LoaizaBonilla A, Kittaneh M, et al. Successful use of trastuzumab with anthracyclinebased chemotherapy followed by trastuzumab maintenance in patients with advanced HER2positive gastric cancer［J］. Anticancer Res, 2014, 34(1): 301306. ［16］ Wll E, Thaler J, Keil F, et al. Oxaliplatin/irinotecan/bevacizumab followed by docetaxel/bevacizumab in inoperable locally advanced or metastatic gastric cancer patients—AGMT_GASTRIC3［J］. Anticancer Res, 2017, 37(10): 55535558. DOI: 10.21873/anticanres.11987. ［17］ Meulendijks D, de Groot JW, Los M, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as firstline treatment of patients with advanced HER2negative gastric cancer: a multicenter phase 2 study［J］. Cancer, 2016, 122(9): 14341443. DOI: 10.1002/cncr.29864. ［18］ Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial［J］. Lancet, 2014, 383(9911): 3139. DOI: 10.1016/S01406736(13)617195. ［19］ Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(11): 12241235. DOI: 10.1016/S14702045(14)704206. ［20］ Di Bartolomeo M, Niger M, Morano F, et al. Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of firstline chemotherapy in patients with advanced HER2 negative gastric or gastroesophageal junction cancers: the ARMANI phase Ⅲ trial［J］. BMC Cancer, 2019, 19(1): 283. DOI: 10.1186/s1288501954983. ［21］ Maron SB, Catenacci DV. Novel targeted therapies for esophagogastric cancer［J］. Surg Oncol Clin N Am, 2017, 26(2): 293312. DOI: 10.1016/j.soc.2016.10.002. ［22］ Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent nonsmallcell lung cancer (JAVELIN solid tumor): doseexpansion cohort of a multicentre, openlabel, phase 1b trial［J］. Lancet Oncol, 2017, 18(5): 599610. DOI: 10.1016/S14702045(17)302401. ［23］ Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an openlabel, phase 1 trial［J］. Lancet Oncol, 2018, 19(1): 5164. DOI: 10.1016/S14702045(17)309002. ［24］ Chung HC, Arkenau HT, Lee J, et al. Avelumab (antiPDL1) as firstline switchmaintenance or secondline therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN solid tumor trial［J］. J Immunother Cancer, 2019, 7(1): 3039. DOI: 10.1186/s4042501905081. ［25］戴韵峰, 郭震浪, 程晶, 等. 中医辨证论治联合化疗治疗晚期非小细胞肺癌的Meta分析［J］. 中国实验方剂学杂志, 2016, 22(2): 180185. DOI: 10.13422/j.cnki.Syfjx.2016020180. ［26］ Wang Q, Wang Q, Wang SF, et al. Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced nonsmallcell lung cancer: a systematic review and metaanalysis［J］. Curr Oncol, 2017, 24(4): e269e276. DOI: 10.3747/co.24.3561. ［27］张朋, 刘苓霜, 姜怡, 等. 病证结合的中医药维持治疗方案干预晚期非小细胞肺癌免疫逃逸的临床研究［J］. 中华中医药杂志, 2018, 33(11): 52345239.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[4]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[5]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[6]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[9]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[10]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[13]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[14]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[15]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.